Tirzepatide is the active ingredient in Mounjaro, Eli Lilly’s diabetes drug, and Zepbound, the company’s weight loss medication. While the shortage has passed, patients and prescribers may still encounter intermittent localized supply disruptions as products move through the supply chain, according to a Oct. 2 news release from the agency.
The FDA noted that other GLP-1 medications, including dulaglutide, semaglutide and liraglutide injections, remain in shortage. The agency said it will continue to collaborate with manufacturers to monitor and address ongoing supply issues.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
